FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2220294725> ?p ?o ?g. }

• W2220294725 endingPage "527.e4" @default.
• W2220294725 startingPage "519" @default.
• W2220294725 abstract "•Evacetrapib 100-mg monotherapy-lowered Lp(a) concentrations by 32%. •Evacetrapib 100 mg with a statin-lowered Lp(a) concentrations by 31%. •Evacetrapib 100-mg monotherapy-lowered sLDL particle concentrations by 84%. •Evacetrapib 100 mg with a statin-lowered sLDL particle concentrations by 60%. •Statin monotherapy had no effect on Lp(a) and sLDL particle concentrations. Background Potent CETP inhibitors reduce plasma concentrations of atherogenic lipoprotein biomarkers of cardiovascular risk. Objectives To evaluate the effects of the cholesteryl ester transfer protein (CETP) inhibitor evacetrapib, as monotherapy or with statins, on atherogenic apolipoprotein B (apoB)–containing lipoproteins in mildly hypercholesterolemic patients. Methods VLDL and LDL particle concentrations and sizes (using nuclear magnetic resonance spectroscopy) and lipoprotein(a) concentration (using nephelometry) were measured at baseline and week 12 in a placebo-controlled trial of 393 patients treated with evacetrapib as monotherapy (30 mg/d, 100 mg/d, or 500 mg/d) or in combination with statins (100 mg plus simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d; Clinicaltrials.gov Identifier: NCT01105975). Results Evacetrapib monotherapy resulted in significant placebo-adjusted dose-dependent decreases from baseline in Lp(a) (up to −40% with evacetrapib 500 mg), total LDL particle (LDL-P) (up to −54%), and small LDL particle (sLDL) (up to −95%) concentrations. Compared to statin alone, coadministration of evacetrapib and statins also resulted in significant reduction from baseline in Lp(a) (−31%), LDL-P (−22%), and sLDL (−60%) concentrations. The percentage of patients with concentrations above optimal concentrations for LDL-P (>1000 nmol/L) and sLDL (>600 nmol/L) decreased from 88% and 55% at baseline, respectively, to 20% and 12% at week 12, for patients treated with evacetrapib plus statins. Evacetrapib, alone or with statins, significantly increased LDL-P size. Conclusions Evacetrapib, as monotherapy or with statins, significantly reduces the concentrations of atherogenic apoB-containing lipoproteins, including Lp(a), LDL-P, and sLDL. Potent CETP inhibitors reduce plasma concentrations of atherogenic lipoprotein biomarkers of cardiovascular risk. To evaluate the effects of the cholesteryl ester transfer protein (CETP) inhibitor evacetrapib, as monotherapy or with statins, on atherogenic apolipoprotein B (apoB)–containing lipoproteins in mildly hypercholesterolemic patients. VLDL and LDL particle concentrations and sizes (using nuclear magnetic resonance spectroscopy) and lipoprotein(a) concentration (using nephelometry) were measured at baseline and week 12 in a placebo-controlled trial of 393 patients treated with evacetrapib as monotherapy (30 mg/d, 100 mg/d, or 500 mg/d) or in combination with statins (100 mg plus simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d; Clinicaltrials.gov Identifier: NCT01105975). Evacetrapib monotherapy resulted in significant placebo-adjusted dose-dependent decreases from baseline in Lp(a) (up to −40% with evacetrapib 500 mg), total LDL particle (LDL-P) (up to −54%), and small LDL particle (sLDL) (up to −95%) concentrations. Compared to statin alone, coadministration of evacetrapib and statins also resulted in significant reduction from baseline in Lp(a) (−31%), LDL-P (−22%), and sLDL (−60%) concentrations. The percentage of patients with concentrations above optimal concentrations for LDL-P (>1000 nmol/L) and sLDL (>600 nmol/L) decreased from 88% and 55% at baseline, respectively, to 20% and 12% at week 12, for patients treated with evacetrapib plus statins. Evacetrapib, alone or with statins, significantly increased LDL-P size. Evacetrapib, as monotherapy or with statins, significantly reduces the concentrations of atherogenic apoB-containing lipoproteins, including Lp(a), LDL-P, and sLDL." @default.
• W2220294725 created "2016-06-24" @default.
• W2220294725 creator A5021765935 @default.
• W2220294725 creator A5021809579 @default.
• W2220294725 creator A5040589473 @default.
• W2220294725 creator A5042273234 @default.
• W2220294725 creator A5055849986 @default.
• W2220294725 creator A5057449551 @default.
• W2220294725 creator A5078102975 @default.
• W2220294725 creator A5078824497 @default.
• W2220294725 creator A5082331899 @default.
• W2220294725 date "2016-05-01" @default.
• W2220294725 modified "2023-10-13" @default.
• W2220294725 title "Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients" @default.
• W2220294725 cites W1488193441 @default.
• W2220294725 cites W1520609538 @default.
• W2220294725 cites W1574102128 @default.
• W2220294725 cites W1856460279 @default.
• W2220294725 cites W1928337672 @default.
• W2220294725 cites W1967021411 @default.
• W2220294725 cites W1979378269 @default.
• W2220294725 cites W1984875752 @default.
• W2220294725 cites W2006909813 @default.
• W2220294725 cites W2026387613 @default.
• W2220294725 cites W2037669982 @default.
• W2220294725 cites W2042127288 @default.
• W2220294725 cites W2050758709 @default.
• W2220294725 cites W2052624323 @default.
• W2220294725 cites W2053585701 @default.
• W2220294725 cites W2055823448 @default.
• W2220294725 cites W2072710993 @default.
• W2220294725 cites W2083315579 @default.
• W2220294725 cites W2084336658 @default.
• W2220294725 cites W2090464684 @default.
• W2220294725 cites W2098890974 @default.
• W2220294725 cites W2104650041 @default.
• W2220294725 cites W2106951652 @default.
• W2220294725 cites W2109429564 @default.
• W2220294725 cites W2109806543 @default.
• W2220294725 cites W2113438133 @default.
• W2220294725 cites W2135757495 @default.
• W2220294725 cites W2142677708 @default.
• W2220294725 cites W2145167597 @default.
• W2220294725 cites W2154836846 @default.
• W2220294725 cites W2155110384 @default.
• W2220294725 cites W2159243445 @default.
• W2220294725 cites W2163238468 @default.
• W2220294725 cites W2164089346 @default.
• W2220294725 cites W2165605025 @default.
• W2220294725 cites W2193506619 @default.
• W2220294725 cites W2247997571 @default.
• W2220294725 cites W2523748108 @default.
• W2220294725 cites W2530844910 @default.
• W2220294725 cites W2790060225 @default.
• W2220294725 doi "https://doi.org/10.1016/j.jacl.2015.11.014" @default.
• W2220294725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27206939" @default.
• W2220294725 hasPublicationYear "2016" @default.
• W2220294725 type Work @default.
• W2220294725 sameAs 2220294725 @default.
• W2220294725 citedByCount "35" @default.
• W2220294725 countsByYear W22202947252016 @default.
• W2220294725 countsByYear W22202947252017 @default.
• W2220294725 countsByYear W22202947252018 @default.
• W2220294725 countsByYear W22202947252019 @default.
• W2220294725 countsByYear W22202947252020 @default.
• W2220294725 countsByYear W22202947252021 @default.
• W2220294725 countsByYear W22202947252022 @default.
• W2220294725 countsByYear W22202947252023 @default.
• W2220294725 crossrefType "journal-article" @default.
• W2220294725 hasAuthorship W2220294725A5021765935 @default.
• W2220294725 hasAuthorship W2220294725A5021809579 @default.
• W2220294725 hasAuthorship W2220294725A5040589473 @default.
• W2220294725 hasAuthorship W2220294725A5042273234 @default.
• W2220294725 hasAuthorship W2220294725A5055849986 @default.
• W2220294725 hasAuthorship W2220294725A5057449551 @default.
• W2220294725 hasAuthorship W2220294725A5078102975 @default.
• W2220294725 hasAuthorship W2220294725A5078824497 @default.
• W2220294725 hasAuthorship W2220294725A5082331899 @default.
• W2220294725 hasConcept C126322002 @default.
• W2220294725 hasConcept C134018914 @default.
• W2220294725 hasConcept C142724271 @default.
• W2220294725 hasConcept C204787440 @default.
• W2220294725 hasConcept C27081682 @default.
• W2220294725 hasConcept C2776329913 @default.
• W2220294725 hasConcept C2776839432 @default.
• W2220294725 hasConcept C2777482532 @default.
• W2220294725 hasConcept C2778163477 @default.
• W2220294725 hasConcept C2780072125 @default.
• W2220294725 hasConcept C2780499067 @default.
• W2220294725 hasConcept C2911022245 @default.
• W2220294725 hasConcept C45505151 @default.
• W2220294725 hasConcept C62746215 @default.
• W2220294725 hasConcept C71924100 @default.
• W2220294725 hasConcept C8243546 @default.
• W2220294725 hasConcept C98274493 @default.
• W2220294725 hasConceptScore W2220294725C126322002 @default.
• W2220294725 hasConceptScore W2220294725C134018914 @default.
• W2220294725 hasConceptScore W2220294725C142724271 @default.

• next